Literature DB >> 1990960

Bronchoalveolar lavage analysis in Wegener's granulomatosis. A method to study disease pathogenesis.

G S Hoffman1, J M Sechler, J I Gallin, J H Shelhamer, A Suffredini, F P Ognibene, R J Baltaro, T A Fleisher, R Y Leavitt, W D Travis.   

Abstract

A prospective analysis of bronchoalveolar lavage (BAL) in 13 patients with Wegener's granulomatosis (WG), 20 disease control subjects with idiopathic pulmonary fibrosis (IPF), and 24 normal control subjects was conducted to (1) evaluate the quality of the alveolar inflammatory response associated with active WG; (2) determine whether antineutrophil cytoplasmic antibody (ANCA) is present in alveolar fluid and produced in the lungs of patients with WG; and (3) determine whether inhaled particles or infectious agents may play an etiologic role in WG. BAL in untreated active WG had a marked increase in neutrophils (mean = 42% of total WBC count), and usually in eosinophils (mean = 4%) compared with that in normal control subjects (1.6% neutrophils, 0% eosinophils), and untreated WG in remission (5.9% neutrophils, 0% eosinophils). Disease control subjects with IPF, a process known to be associated with neutrophilic alveolitis, had an increased population of neutrophils (15.4%) and eosinophils (2.7%) in BAL. Leukocyte remnants, as well as intact leukocytes, could be identified within BAL macrophages in the patients with WG and IPF, and rarely in the normal control subjects. Normal subjects and control patients with IPF were all negative for ANCA in serum, whereas ANCA was found in serum and BAL in all patients with active WG who had generalized disease. Protein analysis of BAL revealed a disproportionate increase in the IgG to albumin ration compared with serum values (IgG index) in patients with active untreated disease. The increase in the IgG index suggests that IgG with ANCA reactivity is produced by pulmonary lymphoid tissue. An infectious agent in BAL was not identified by any of the techniques applied in this study.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990960     DOI: 10.1164/ajrccm/143.2.401

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  7 in total

Review 1.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome.

Authors:  A Schnabel; E Csernok; J Braun; W L Gross
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 3.  Pulmonary vasculitis.

Authors:  A Burns
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 4.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

5.  C-ANCA-positive IgG fraction from patients with Wegener's granulomatosis induces lung vasculitis in rats.

Authors:  W Weidebach; V S T Viana; E P Leon; C Bueno; A S Leme; F M Arantes-Costa; M A Martins; P H N Saldiva; E Bonfa
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

6.  Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders.

Authors:  J W Tervaert; L Mulder; C Stegeman; J Elema; M Huitema; H The; C Kallenberg
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

7.  Upper respiratory tract symptoms, renal involvement and vasculitis: a case report and review of wegener granulomatosis.

Authors:  Mohd Shahrir Mohamed Said
Journal:  J Clin Med Res       Date:  2010-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.